The use of combination advanced therapies in psoriatic arthritis: results from a UK multi-centre audit.
作者信息
Jethwa Hannah, Gudu Tania, Coates Laura C, Helliwell Philip S, Tillett William, Abuelmagd Abdalla, Andev Rajinder S, Ashraf Madiha, Baqai Tanya, Choy Ernest, Das Dhivya, Gullick Nicola, Heighton Catherine, Kinder Alison, Laxminarayan Ramasharan, Mittal Gayatri, Morris Penelope, Mukherjee Sandeep, Nandagudi Anupama, Rangaraj Satyapal, Sharma Poonam, Temple Hoda, Traub Beverly, Paisal Vishal, Hum Ryan, Vivekanantham Arani, Wilson Robert, Jadon Deepak
机构信息
Department of Medicine, University of Cambridge, Cambridge, UK.
Rheumatology Department, Cambridge University Hospitals NHSFT, Cambridge, UK.
出版信息
Rheumatology (Oxford). 2025 May 1;64(5):3173-3176. doi: 10.1093/rheumatology/keaf037.
Abstract
摘要
相似文献
1
The use of combination advanced therapies in psoriatic arthritis: results from a UK multi-centre audit.联合使用先进疗法治疗银屑病关节炎：英国多中心审计结果
Rheumatology (Oxford). 2025 May 1;64(5):3173-3176. doi: 10.1093/rheumatology/keaf037.
2
Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial.早期银屑病关节炎炎症严格控制的效果（TICOPA）：一项英国多中心、开放标签、随机对照试验。
Lancet. 2015 Dec 19;386(10012):2489-98. doi: 10.1016/S0140-6736(15)00347-5. Epub 2015 Oct 1.
3
Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis.性别相关的患者特征差异，以及在随机临床试验中接受高级治疗的银屑病关节炎患者的疗效和安全性：系统文献回顾和荟萃分析。
Lancet Rheumatol. 2023 Dec;5(12):e716-e727. doi: 10.1016/S2665-9913(23)00264-3. Epub 2023 Nov 14.
4
Psoriatic arthritis treatment regimens, therapy duration and reasons for cessation in the biologics era: a multi-centre Australian study.生物制剂时代银屑病关节炎的治疗方案、治疗持续时间及停药原因：一项澳大利亚多中心研究
Int J Rheum Dis. 2018 Feb;21(2):510-516. doi: 10.1111/1756-185X.13127. Epub 2017 Jul 21.
5
Treatment patterns, unmet need, and impact on patient-reported outcomes of psoriatic arthritis in the United States and Europe.美国和欧洲银屑病关节炎的治疗模式、未满足的需求及其对患者报告结局的影响。
Rheumatol Int. 2019 Jan;39(1):121-130. doi: 10.1007/s00296-018-4195-x. Epub 2018 Nov 13.
6
Is precision medicine possible in rheumatic diseases? Lessons from selective use of targeted therapies in patients with psoriatic arthritis.精准医学在风湿性疾病中可行吗？来自银屑病关节炎患者靶向治疗选择性应用的经验教训。
Expert Rev Clin Immunol. 2020 Feb;16(2):199-206. doi: 10.1080/1744666X.2019.1706484. Epub 2020 Jan 6.
7
Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: A Systematic Literature Review.治疗银屑病关节炎的成本和成本效益：系统文献回顾。
Pharmacoeconomics. 2018 May;36(5):567-589. doi: 10.1007/s40273-018-0618-5.
8
Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis.阿普司特与生物制剂联合治疗作为银屑病关节炎和银屑病的安全选择
Curr Rheumatol Rev. 2019;15(3):234-237. doi: 10.2174/1573397115666181130094455.
9
Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis.依那西普治疗银屑病和银屑病关节炎的长期疗效与安全性。
Biologics. 2014 Apr 17;8:169-82. doi: 10.2147/BTT.S41481. eCollection 2014.
10
Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis (COMPLETE-PsA): a double-blind, placebo-controlled, randomised, trial.甲氨蝶呤单药疗法与甲氨蝶呤联合来氟米特治疗银屑病关节炎的比较（COMPLETE-PsA）：一项双盲、安慰剂对照、随机试验。
Lancet Rheumatol. 2022 Apr;4(4):e252-e261. doi: 10.1016/S2665-9913(22)00028-5. Epub 2022 Feb 28.
本文引用的文献
1
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.古塞库单抗联合戈利木单抗与古塞库单抗或戈利木单抗单药治疗溃疡性结肠炎患者的疗效比较（VEGA）：一项随机、双盲、对照、2期概念验证试验
Lancet Gastroenterol Hepatol. 2023 Apr;8(4):307-320. doi: 10.1016/S2468-1253(22)00427-7. Epub 2023 Feb 1.
2
Phenotypic heterogeneity in psoriatic arthritis: towards tissue pathology-based therapy.银屑病关节炎的表型异质性：迈向基于组织病理学的治疗
Nat Rev Rheumatol. 2023 Mar;19(3):153-165. doi: 10.1038/s41584-022-00874-5. Epub 2023 Jan 3.
3
Combination Therapy With Tofacitinib and IL-12/23, IL-23, or IL-17A Inhibition for the Treatment of Refractory Psoriatic Arthritis: A Case Series.托法替布与IL-12/23、IL-23或IL-17A抑制联合治疗难治性银屑病关节炎：病例系列
J Clin Rheumatol. 2022 Mar 1;28(2):e626-e628. doi: 10.1097/RHU.0000000000001767.
4
Induction of remission in biologic-naive, severe psoriasis and PsA with dual anti-cytokine combination.使用双抗细胞因子联合疗法诱导初治的重度银屑病和银屑病关节炎缓解。
Rheumatology (Oxford). 2021 Jul 1;60(7):e225-e226. doi: 10.1093/rheumatology/keaa880.
5
A comparison of apremilast monotherapy and combination therapy for psoriatic arthritis in a real-life setting: Data from the Leeds Combined Psoriatic Service.现实环境中阿普米拉斯单药治疗与联合治疗银屑病关节炎的比较：来自利兹综合银屑病服务的数据。
J Am Acad Dermatol. 2019 Jun;80(6):1796-1798. doi: 10.1016/j.jaad.2019.02.014. Epub 2019 Feb 13.
6
Combined inhibition of tumour necrosis factor-alpha and interleukin-12/23 for long-standing, refractory psoriatic disease: a differential role for cytokine pathways?联合抑制肿瘤坏死因子-α和白细胞介素-12/23治疗长期难治性银屑病：细胞因子通路的不同作用？
Rheumatology (Oxford). 2018 Nov 1;57(11):2053-2055. doi: 10.1093/rheumatology/key199.
7
Phase II Study of ABT-122, a Tumor Necrosis Factor- and Interleukin-17A-Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate.ABT-122（一种针对肿瘤坏死因子和白细胞介素-17A 的双可变域免疫球蛋白）治疗甲氨蝶呤应答不足的银屑病关节炎的 II 期研究。
Arthritis Rheumatol. 2018 Nov;70(11):1778-1789. doi: 10.1002/art.40579.
Zotero 插件